Toxic effects of dopamine metabolism in Parkinson's disease

Parkinsonism & Related Disorders
Nobutaka HattoriaHideki Mochizuki

Abstract

Levodopa is the most effective medication for Parkinson's disease (PD). In contrast, there is evidence that levodopa and its metabolites such as dopa/dopamine quinone are toxic for nigral neurons based on in vitro studies. Moreover, there is growing evidence that oxidative stress and mitochondrial dysfunction contribute the pathogenesis of PD. Thus, studies for oxidative stress give us good information for elucidating the pathogenesis of PD. In this regard, it is mandatory to develop markers such as 4-hydroxy-nonenal (HNE). HNE is a product of lipid peroxidation. Indeed, immunohistochemical studies have revealed that HNE-modified proteins accumulate within ragged red fibers (RRFs). This finding indicated that mitochondrial impairment may be linked to oxidative stress. Moreover, HNE-modified proteins accumulate in nigral neurons. In PD, mitochondrial dysfunction such as complex I deficiency has also been reported. In addition, HNE can modify alpha-synuclein (SNCA). Subsequently, this modification may trigger the aggregation of this protein. At a minimum, this modification could be associated with oligomer formation or fibrillation of SNCA.

References

Sep 29, 2004·Lancet·Marie-Christine Chartier-HarlinAlain Destée

❮ Previous
Next ❯

Citations

Aug 27, 2010·Acta Neuropathologica·Alipi V NaydenovChristine Konradi
Feb 22, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Marie-Francoise ChesseletSudhakar R Subramaniam
Aug 4, 2012·ACS Chemical Neuroscience·Tiffiny ChanKagan Kerman
Oct 2, 2012·DNA and Cell Biology·Monica ColamartinoRenata Cozzi
Dec 25, 2012·Disease Models & Mechanisms·Matthew C HavrdaKathryn B Holroyd
Nov 26, 2010·Journal of Clinical Biochemistry and Nutrition·Takako ShimizuSeiichi Matsugo
Apr 16, 2010·Canadian Journal of Physiology and Pharmacology·Joseph K EiblGregory M Ross
Sep 20, 2011·Journal of Biotechnology·Tiziana Alberio, Mauro Fasano
Sep 9, 2015·Behavioral and Brain Functions : BBF·Maria VadalàTommaso Iannitti
Jul 15, 2016·Oxidative Medicine and Cellular Longevity·Sandesh PanthiNa Young Jeong
Aug 18, 2010·Neuro-degenerative Diseases·Raquel DuranFrancisco Vives
Jan 9, 2017·Free Radical Biology & Medicine·Adele RomanoSilvana Gaetani
Sep 19, 2012·Neuroimmunomodulation·Marina A GrudenRobert D E Sewell
Jul 30, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Emanuele CeredaGianni Pezzoli
Feb 13, 2016·Toxicological Sciences : an Official Journal of the Society of Toxicology·Samuel W Caito, Michael Aschner
Aug 15, 2017·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·V A KashkinV G Makarov
Feb 1, 2020·Current Pharmaceutical Design·Hayrettin O Gülcan, Ilkay E Orhan
Aug 11, 2020·Oxidative Medicine and Cellular Longevity·Andrés García-SánchezErnesto Germán Cardona-Muñoz
Sep 17, 2011·The Journal of Physical Chemistry. B·Cristina IugaAnnik Vivier-Bunge

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alpha-Synuclein Aggregation

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Related Papers

The Journal of Pharmacology and Experimental Therapeutics
C MytilineouC Warren Olanow
Human Molecular Genetics
Mark R Cookson, Oliver Bandmann
The New England Journal of Medicine
Peter A Lewitt
© 2021 Meta ULC. All rights reserved